Beta Bionics director granted 3,997 stock units
Beta Bionics, Inc. director Sean Carney reported a stock-based award.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Beta Bionics, Inc. director Sean Carney reported a stock-based award. On 01/13/2026, he acquired 3,997 shares of common stock at a price of $0, described as a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. After this grant, he beneficially owned 15,244 shares of Beta Bionics common stock, held directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 3,997 | $0.00 | $0.00 |
Footnotes (1)
- F1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Beta Bionics (BBNX) disclose about director Sean Carney in this Form 4?
The filing shows that director Sean Carney acquired 3,997 shares of Beta Bionics common stock on 01/13/2026 through a restricted stock unit award under the company’s 2025 Equity Incentive Plan.
What plan was used for the restricted stock unit award to Sean Carney at Beta Bionics?
The 3,997-share award is described as a restricted stock unit award granted under Beta Bionics’ 2025 Equity Incentive Plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.